91 related articles for article (PubMed ID: 28035374)
1. Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors.
Swerev TM; Wirth T; Ushmorov A
Int J Oncol; 2017 Feb; 50(2):555-566. PubMed ID: 28035374
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.
Ushmorov A; Leithäuser F; Sakk O; Weinhaüsel A; Popov SW; Möller P; Wirth T
Blood; 2006 Mar; 107(6):2493-500. PubMed ID: 16304050
[TBL] [Abstract][Full Text] [Related]
4. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.
Baus D; Nonnenmacher F; Jankowski S; Döring C; Bräutigam C; Frank M; Hansmann ML; Pfitzner E
Leukemia; 2009 Oct; 23(10):1885-93. PubMed ID: 19440213
[TBL] [Abstract][Full Text] [Related]
5. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Yuki H; Ueno S; Tatetsu H; Niiro H; Iino T; Endo S; Kawano Y; Komohara Y; Takeya M; Hata H; Okada S; Watanabe T; Akashi K; Mitsuya H; Okuno Y
Blood; 2013 Feb; 121(6):962-70. PubMed ID: 23212521
[TBL] [Abstract][Full Text] [Related]
6. The role of DNA methylation and histone acetylation in the regulation of progesterone receptor isoforms expression in human astrocytoma cell lines.
Hansberg-Pastor V; González-Arenas A; Peña-Ortiz MA; García-Gómez E; Rodríguez-Dorantes M; Camacho-Arroyo I
Steroids; 2013 May; 78(5):500-7. PubMed ID: 23474171
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.
Ushmorov A; Ritz O; Hummel M; Leithäuser F; Möller P; Stein H; Wirth T
Blood; 2004 Nov; 104(10):3326-34. PubMed ID: 15284123
[TBL] [Abstract][Full Text] [Related]
9. Resistance to 5-aza-2'-deoxycytidine in genic regions compared to non-genic repetitive sequences.
Lim HW; Iwatani M; Hattori N; Tanaka S; Yagi S; Shiota K
J Reprod Dev; 2010 Feb; 56(1):86-93. PubMed ID: 19996551
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of microRNA expression in Hodgkin lymphoma.
Navarro A; Díaz T; Cordeiro A; Beyá MD; Ferrer G; Fuster D; Martinez A; Monzó M
Leuk Lymphoma; 2015; 56(9):2683-9. PubMed ID: 25586608
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Liu Y; Huang R; Liu L; Meng Y; Liu X
Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
[TBL] [Abstract][Full Text] [Related]
13. FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.
Xie L; Ritz O; Leithäuser F; Guan H; Färbinger J; Weitzer CD; Gehringer F; Bruederlein S; Holzmann K; Vogel MJ; Möller P; Wirth T; Ushmorov A
Oncotarget; 2014 Jul; 5(14):5392-402. PubMed ID: 24977668
[TBL] [Abstract][Full Text] [Related]
14. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.
Bohle V; Döring C; Hansmann ML; Küppers R
Leukemia; 2013 Mar; 27(3):671-9. PubMed ID: 23174882
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature.
Serravalle S; Bertuccio SN; Astolfi A; Melchionda F; Pession A
Biomed Res Int; 2016; 2016():1985750. PubMed ID: 28003999
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.
Patel R; Shervington L; Lea R; Shervington A
Brain Res; 2008 Jan; 1188():173-81. PubMed ID: 18021753
[TBL] [Abstract][Full Text] [Related]
17. Increased sensitivity of nontumorigenic fibroblasts expressing ras or myc oncogenes to malignant transformation induced by 5-aza-2'-deoxycytidine.
Rimoldi D; Srikantan V; Wilson VL; Bassin RH; Samid D
Cancer Res; 1991 Jan; 51(1):324-30. PubMed ID: 1703037
[TBL] [Abstract][Full Text] [Related]
18. Increased IFNγ
Li X; Zhang Y; Chen M; Mei Q; Liu Y; Feng K; Jia H; Dong L; Shi L; Liu L; Nie J; Han W
Clin Cancer Res; 2017 Oct; 23(20):6031-6043. PubMed ID: 28706011
[No Abstract] [Full Text] [Related]
19. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
20. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
